TECregen Appoints Drug Development Veteran Dr. Klaas P. Zuideveld as Chief Executive Officer to Lead Thymus Regeneration Platform into Clinical Development
PR Newswire —
Appointment builds on CHF 10 million seed financing and Board leadership expansion BASEL, Switzerland, Jan. 29, 2026 /PRNewswire/ -- TECregen, a biotechnology company pioneering thymus rejuvenation, today announced the appointment of Dr. Klaas P. Zuideveld, Ph.D., as Chief Executive...